Smallpox Antiviral

Awarded Limited / Sole Source Justification Posted

Solicitation number
75A50122C00047
Agency
Set-aside
No set-aside

Opportunity facts

Contract number
75A50122C00047 Federal contract award

Notice details come from SAM.gov. Updated .

About this opportunity

This Limited/Sole Source Justification Notice is for the continued development and manufacture of up to 1.7 million treatment courses of the smallpox antiviral brincidofovir under the trade name TEMBEXA by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The justification cites that Chimerix, Inc. is currently the only company with a smallpox therapeutic approved by the FDA with a distinct mechanism of action from the only other approved smallpox drug. The contract was awarded solely to Chimerix on August 26, 2022 for an undisclosed amount to supply the Strategic National Stockpile and conduct associated activities.

Notice text

The scope of work for this contract (across the Base and Option periods)
includes the manufacture and delivery of up to 1.7 Million Treatment Courses (TCs) of the smallpox
antiviral TEMBEXA, comprising oral tablets and oral suspension formulation to the SNS and the
associated activities.

Awarded contract 75A50122C00047 to unknown vendor for unknown amount on 2022-08-26.

Files

Notice history

Notice Type Posted
This notice Latest Limited / Sole Source Justification
Smallpox Antiviral Award Award Notice
Smallpox Antiviral Latest solicitation Solicitation
Smallpox Antiviral Pre-Solicitation
Smallpox Antiviral Original Pre-Solicitation

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors